Role of macrophages in control of ocular HSV

巨噬细胞在控制眼部 HSV 中的作用

基本信息

  • 批准号:
    9144799
  • 负责人:
  • 金额:
    $ 43.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-30 至 2018-09-29
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Macrophage infiltrates play a variety of key roles in the immune defense system, including a central role in innate or natural immunity. We have shown by immunostaining using anti-F4/80 and CD11b antibodies that resident corneal macrophages are not detectable in cornea of uninfected mice. In contrast, following infection of mice with herpes simplex virus type-1 (HSV-1), macrophages appear to be the most dominant infiltrate of the eye. Thus, macrophages may play a central role in both exacerbation and control of acute and chronic HSV-1 infection. In line with our previous studies, our Preliminary studies also suggest that: 1. Injection of mice with macrophage-colony stimulating factor (M-CSF) DNA reduced virus replication in the eye and establishment of latency in trigeminal ganglia (TG) of ocularly infected mice. 2. Similar to M-CSF injection, injection of mice with IL-12p35 DNA also reduced virus replication in the eye and establishment of latency in TGs of latently infected mice. Thus, since macrophages are the most abundant infiltrates in the eye of HSV-1 ocularly infected mice and also appear the fastest in the eye (as early as 4 hours) after ocular infection, we will use macrophage stimulatory factors (i.e., M-CSF and IL-12p35) to reduce virus replication in the eye and establishment of latency in the TGs of ocularly infected mice. We propose to: Aim: Test the hypothesis that macrophage stimulation by a combination of IL-12p35 and M-CSF DNA as molecular adjuvants will enhance TH1/TC1 responses in the eye and lead to a more rapid clearance of virus from the eye and trigeminal ganglia (TG) during primary ocular HSV-1 infection. This will, lead to a significant reduction in establishment of latency and reactivation in TG of latently infected mice. Our preliminary studies suggest that administration of IL-12p35 and M-CSF DNA improves immunization efficacy as judged by a greater reduction in virus replication in the eye after ocular infection compare with control mice, or mice that are immunized with IL-12p35 or M-CSF alone. This improved efficacy correlated with higher activities of local ocular responses (i.e., IL-2, IFN-a, IFN-ß, IFN- γ). We propose to test the hypothesis that; (1) a cocktail of IL-12p35 and M-CSF DNA will result in reduction in primary virus replication in the eyes as well as reduction of latency in TGs of infected mice; (2) these reductions are associated with generation of strong and rapid TH1/TC1 responses in addition to IFN-a and IFN-ß in the eye and TGs of infected mice; and (3) Co-administration of IL-12p35 + M-CSF + 5gP DNA will further reduce latency in immunized mice compared with mice that treated with 5gP alone. Overall, we expect to determine that a combination of IL-12p35 and M-CSF enhances the cytokine secretion and antigen presentation functions of macrophages rather than their phagocytosis function.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HOMAYON GHIASI其他文献

HOMAYON GHIASI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HOMAYON GHIASI', 18)}}的其他基金

Role of type 1 IFN in eye infection
1 型干扰素在眼部感染中的作用
  • 批准号:
    10732600
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of type 2 Innate Lymphoid Cells (ILC2s) in optic neuritis
2 型先天淋巴细胞 (ILC2) 在视神经炎中的作用
  • 批准号:
    10359644
  • 财政年份:
    2021
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of type 2 Innate Lymphoid Cells (ILC2s) in optic neuritis
2 型先天淋巴细胞 (ILC2) 在视神经炎中的作用
  • 批准号:
    10357860
  • 财政年份:
    2019
  • 资助金额:
    $ 43.75万
  • 项目类别:
Ocular HSV: Mechanism of virus reactivation
眼部 HSV:病毒再激活机制
  • 批准号:
    10165727
  • 财政年份:
    2018
  • 资助金额:
    $ 43.75万
  • 项目类别:
Ocular HSV: Mechanism of virus reactivation
眼部 HSV:病毒再激活机制
  • 批准号:
    10649980
  • 财政年份:
    2018
  • 资助金额:
    $ 43.75万
  • 项目类别:
Therapeutic control of HSK by CD80
CD80 对 HSK 的治疗控制
  • 批准号:
    10357919
  • 财政年份:
    2016
  • 资助金额:
    $ 43.75万
  • 项目类别:
Therapeutic control of HSK by CD80
CD80 对 HSK 的治疗控制
  • 批准号:
    10534160
  • 财政年份:
    2016
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of macrophages in control of ocular HSV
巨噬细胞在控制眼部 HSV 中的作用
  • 批准号:
    9759926
  • 财政年份:
    2015
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of macrophages in control of ocular HSV
巨噬细胞在控制眼部 HSV 中的作用
  • 批准号:
    9330866
  • 财政年份:
    2015
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of macrophages in control of ocular HSV
巨噬细胞在控制眼部 HSV 中的作用
  • 批准号:
    10222691
  • 财政年份:
    2015
  • 资助金额:
    $ 43.75万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了